Cost-minimisation analysis of the pharmacological treatment of epilepsy in Spain

• Published in: Revista de neurologiá Vol. 42; no. 5; pp. 257 - 264
• Main Authors: Rubio, M, Lizán, L, Badia, X, Escartín-Siquier, A E, López-Trigo, J, Rufo-Campos, M, Echarri, E
• Format: Journal Article
• Language: Spanish
• Published: Spain 01.03.2006
• Subjects: Anticonvulsants - economics; Anticonvulsants - therapeutic use; Cost of Illness; Cost-Benefit Analysis; Decision Making; Drug Costs; Economics, Pharmaceutical; Epilepsy - drug therapy; Epilepsy - economics; Humans; Models, Econometric; Treatment Outcome
• ISSN: 0210-0010
• DOI: 10.33588/rn.4205.2005356

To use a model of economic evaluation to analyse the efficiency of therapy with the antiepileptic drugs indicated in recently diagnosed partial and generalised epilepsy. The treatment of partial epilepsy and generalised epilepsy in Spain was taken as the basis to design two flexible simulation models of the decision tree type. The time horizon of the study was one year and the perspective was that of the Spanish National Health System, and indirect costs were also included. Clinical effectiveness data were obtained from a review of the literature on clinical trials. Information about resources was obtained from the opinions of a panel of experts. Unitary costs of resources were drawn from Spanish databases (euro 2003). The findings of the study were expressed in terms of average cost per patient with each therapeutic strategy, as well as the incremental cost of the different treatment strategies with respect to valproic acid. According to the literature that was reviewed, there are no differences in effectiveness from one antiepileptic drug to another. The incremental cost of the different therapeutic strategies, with respect to valproic acid, lies between 211 and 911 euros per patient and year in partial epilepsy, and between 1,355 and 1,297 euros per patient and year in the case of generalised epilepsy. The use of sustained-release valproic acid in recently diagnosed partial and generalised epilepsy would allow savings to be made in resources, with respect to the other antiepileptic drugs, and can therefore be considered to be the most effective therapeutic option.